Anti-angiogenic therapy for metastatic colorectal cancer

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Wagner, Anna Dorothea ^a   Unverzagt, S ^b   Grothey, A ^b   Arnold, D ^b   Sargent, D ^b   Haerting, J ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; HUMAN; META ANALYSIS; METASTASIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW;

EID: 44949220272     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005392.pub2     Document Type: Review

References (42)

1. Altman 2001 Altman DG. Systematic reviews of evaluations of prognostic variables. Systematic reviews in health care. 2nd Edition. London: BMJ, 2001:228-47.
2. Am. Cancer Soc. 2005 American Cancer Society. Cancer Facts and Figures. Cancer Facts and Figures 2005.
3. Bergers 2003 Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nature Reviews Cancer 2003;3(6):401-410. [MEDLINE: 24].
4. Cao 2004 Cao YH. Antiangiogenic cancer therapy. Seminars in Cancer Biology 2004;14(2):139-145. [MEDLINE: 25].
5. Cox 1972 Cox DR. Regression models and life tables. Journal of the Royal Statistical Society 1972;34(Series B):187-220.
6. CRC Meta-anal. 2000 Colorectal Meta-analysis Collaboration. Palliative chemotherapy for advanced or metastatic colorectal cancer:. Cochrane Database of Systematic Reviews 2002, issue 2. [MEDLINE: 7].
7. de Gramont 2000 de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology 2000;18(16):2938-2947. [MEDLINE: 12].
8. Douillard 2000 Douillard JY, Cunningham D, Roth AD, Navarro M, James RD. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. The Lancet 2000;355(9209):1041-7.
9. Dvorak 2002 Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. Journal of Clinical Oncology 2002;20(21):4368-4380. [MEDLINE: 23].
10. EMEA 2002 Points to consider on multiplicity issues in clinical trials. available under: http://www.emea.europa.eu/pdfs/human/ewp/090899en.pdf.
11. Ferrara 2004 Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews Drug Discovery 2004;3(5):391-400. [MEDLINE: 32].
12. Fidler 1994 Fidler IJ, Ellis LM. The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis. Cell 1994;79(2):185-188. [MEDLINE: 26].
13. Folkman 1971 Folkman J, Bach M, Rowe JW, Davidoff F, Lambert P, Hirsch C, Goldberg A, Hiatt HH, Glass J, Henshaw E. Tumor Angiogenesis - Therapeutic Implications. New England Journal of Medicine 1971;285(21):1182-&. [MEDLINE: 20].
14. Folkman 1990 Folkman J. What Is the Evidence That Tumors Are Angiogenesis Dependent. Journal of the National Cancer Institute 1990;82(1):4-6. [MEDLINE: 18].
15. Gasparini 2005 Gasparini G, Longo R, Fanielli M, Teicher BA. Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges and Open Questions. Journal of Clinical Oncology 2005;23(6):1295-1311. [MEDLINE: 37].
16. Giacchetti 2000 Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology 2000;18(1):136-47.
17. Gill 2004 Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Seitz JF, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much?. Journal of Clinical Oncology 2004;22(10):1797-1806. [MEDLINE: 3].
18. Grothey 2002 Grothey A, Deschler B, Kroening H, Ridwelski K, Reichardt P, Kretzschmar A, et al.Phase III study of bolus 5-fluorouracil (5-FU)/ folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/ FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc. Annu.Meet.Am.Soc.Clin.Oncol. 2002; Vol. 21:512.
19. Grothey 2004 Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. Journal of Clinical Oncology 2004;22(7):1209- 1214. [MEDLINE: 15].
20. Hamilton 1998 Hamilton JM, Grem JL. Chapter 9: Lower gastrointestinal cancer. In: KirkwoodJM, LotzeMT, YaskoJM editor(s). Current Cancer Therapeutics. Vol. 3, Churchill Livingstone, 1998.
21. Hanahan 1996 Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86(3):353-364. [MEDLINE: 19].
22. Hicklin 2005 Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of Clinical Oncology 2005;23(5):1011-1027. [MEDLINE: 30].
23. Jadad 1996 Jadad MS, Moore A, Carroll D, et al.Assessing the quality of reports of randomized clinical trials: Is blinding neccessary ?. Controlled Clinical Trials 1996;17:1-12.
24. Kakeji 1997 Kakeji Y, Teicher BA. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Investigational New Drugs 1997;15:39-48. [MEDLINE: 36].
25. Longo 2002 Longo R, Sarmiento M, Fanielli M, Capaccetti B, Gattuso D, Gasparini G. Anti-angiogenic therapy: Rationale, challenges and clinical studies. Angiogenesis 2002;5:237-256. [MEDLINE: 34].
26. Lyden 2001 Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu ZP, Hackett NR, Crystal RG, Moore MAS, Hajjar KA, Manova K, Benezra R, Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Medicine 2001;7(11):1194-1201. [MEDLINE: 22].
27. Machin 1997 Machin D, Stenning SP, Parmar MKP, et al.Thirty years of Medical Research Council randomized trials in solid tumors. Journal of Clinical Oncology 1997;9:100-114.
28. McDonald 2002 McDonald DM, Baluk P. Significance of blood vessel leakiness in cancer. Cancer Research 2002;62(18):5381-5385. [MEDLINE: 28].
29. Miller 2005 Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. Journal of Clinical Oncology 2005;23(4):792-799. [MEDLINE: 31].
30. Obrand 1997 Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Diseases of the Colon & Rectum 1997;40(1):15-24. [MEDLINE: 1].
31. Parkin 2001 Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: GLOBOCAN 2000. International Journal of Cancer 2001;94(2):153-156. [MEDLINE: 2].
32. Parmar 1998 Parmar MKB, Torri V, Steward L. Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
33. Rak 1996 Rak J, Kerbel R. Treating cancer by inhibiting angiogenesis: New hopes and potential pitfalls. Cancer Metastasis Reviews 1996;15:231-236. [MEDLINE: 35].
34. Reviewers Handbook Clarke M, Oxman AD, editors. Cochrane Reviewers Handbook 4.2.0 (updated March 2003). The Cochrane Library 2003, issue 2.
35. Riley 2007 Riley RD, Simmonds MC, Look MP. Evidence combining individual patient data and aggregate data: a systematic review identified current practice and possible methods. Journal of Clinical Epidemiology 2007;60(5):431-439.
36. Saltz 2000 Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 2000;343(13):905-914. [MEDLINE: 9].
37. Scheithauer 1993 Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomized Comparison of Combination Chemotherapy Plus Supportive Care with Supportive Care Alone in Patients with Metastatic Colorectalcancer. British Medical Journal 1993;306(6880):752-755. [MEDLINE: 6].
38. Schulz 1994 Schulz KF, Chalmers I, Grimes DA, Altman DG. Assessing the quality of randomization from reports of controlled trials published in Obstetrics and Gynecology Journals. JAMA 1994;272(2):125-8. [MEDLINE: 8015122].
39. Sivakumar 2005 Sivakumar B, Harry L.E, Paleolog EM. Modulating Angiogenesis. JAMA 2005;292(8):972-977. [MEDLINE: 40].
40. Therasse 2000 Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbecke M, van Osterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cance, National Cancer Institute of Canada, National Cancer Institute of the United States. Journal of the National Cancer Institute 2000;92(3):205-216.
41. Whitehead 2002 Whitehead N. In: StevenSenn, VickBarnett editor(s). Statistics in Practice. Chichester: John Wiley and Sons, 2002.
42. Zebrowski 1999 Zebrowski BK, Yano S, Liu WB, Shaheen RM, Hicklin DJ, Putnam JB, Ellis LM. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clinical Cancer Research 1999;5(11):3364-3368. [MEDLINE: 27].